Division of Endo International PLC
Latest From Par Pharmaceutical
Expert witness "battle plan," requests for summary judgment, and squabble over DEA drug distribution data offer preview of the first US bellwether trial against opioid manufacturers, distributors and pharmacies.
Neuraxpharm has appointed Craig Bowen as general manager of its UK affiliate at the same time as the European central nervous system specialist has launched its first products in the UK market.
The biotech’s MS franchise led by Tecfidera grew strongly, while SMA therapy Spinraza dipped slightly, but Biogen maintains optimistic outlook amidst growing competition.
Cipla, which expects to enter the US albuterol inhalation market later this year, believes that it has the cost competitiveness to price “significantly lower” than competition and take a “fair share” of a market that recently saw the arrival of authorized generics.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Par Pharmaceutical Cos. Inc.
- Par Pharmaceutical Holdings Inc.
- Qualitest Pharmaceuticals
- Pharmaceutical Resources Inc.
- North America
- Parent & Subsidiaries
- Endo International PLC
- Senior Management
- Paul V Campanelli, Pres.
- Contact Info
Phone: (845) 573-5500
One Ram Ridge Rd.
Chestnut Ridge, NY 10977
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.